Early HIT diagnostics Retham Technologies is developing HITDx, an in vitro diagnostic assay aimed at early and accurate near-patient HIT diagnosis, presenting a direct sales opportunity to hospital laboratories and point-of-care settings seeking faster, more reliable results than PF4 ELISAs.

Clinical impact focus The product targets a high-stakes clinical problem with potentially life-saving outcomes by reducing false positives and unnecessary non-heparin anticoagulant use, creating a compelling value proposition for hospital procurement teams and clinician champions.

Strategic partnerships Recent seed funding and local investor activity indicate potential for collaborations with regional healthcare systems, contract manufacturers, and distribution partners to accelerate clinical validation, regulatory milestones, and market entry.

SMB biotech traction With a small team yet growing investor interest and a seed round close, there is an opportunity to position Retham as a nimble, innovation-first vendor to mid-size hospitals and community health networks seeking cutting-edge HIT diagnostics.

Tech stack optimization Existing digital infrastructure and cloud-based tools (Wix, Google Cloud, Sentry) suggest potential for scalable online marketing, e-commerce enablement for direct-to-lab sales, and streamlined customer onboarding and support.